Once approved, the manufacturers of medical devices will have to obtain licenses from India’s Drug Controller General (DCGI), while CDSCO will be the nodal authority to investigate the quality, privacy-related violation, grievances, and may revoke the registration based on the inquiry result. The Union Health Ministry has suggested, through a recent notification, to put all medical products, including contraception and implants, under the legal framework of the apex drug regulatory body, Central Drugs and Standard Control Organization (CDSCO), mandating all medical devices to receive CDSCO approval for the licenses. In this regard, the government sought input from all stakeholders within 30 days of the completion of the draft notification, the deadline of adoption in the draft notification is December 1. The suggestions/comments/objections may be sent by email or by post within 30 days of the date of issue of this Notification. The amendment pursues sub-section (b) of section 3 of the 1940 Drugs and Cosmetics Act to control them in accordance with the provisions of the 2017 Medical Devices Act and Medical Devices Regulations. Sub-section (b) of section 3 of the 1940 Drugs and Cosmetics Act applies to all drugs known to be “DRUGS.” In a major move to provide patient safety and control the performance of diagnostic and medical devices in India, Medical Dialogs had reported earlier that eight medical devices, including all implantable devices, had been approved by the Ministry of Health as “drugs” under Section 3 of the Drugs and Cosmetics Act, effective April 1, 2020.